Schizophrenia
Psychiatric patients significantly more likely to be perpetrators and victims of violence
BMI linked to major psychiatric disorders
Lumateperone safe, effective for patients with schizophrenia
Prescribing antipsychotics at higher than 95% effective dose may not offer additional efficacy
Polygenic scores can help determine schizophrenia subgroups
Schizophrenia subgroups with distinct cognitive development trajectories can be determined using adult cognitive data, according to study findings published in American Journal of Psychiatry. Researchers noted that these subgroups have significantly different profiles of cognitive, academic and psychiatric genetic influence.
FDA approves Caplyta for schizophrenia
Having dogs as pets may decrease schizophrenia risk
Q&A: Treatment potential of ALKS 3831 for schizophrenia, bipolar I disorder

Alkermes recently announced submission of a new drug application to the FDA for its investigational schizophrenia treatment ALKS 3831, a combination of olanzapine and samidorphan, for the treatment of schizophrenia and the treatment of bipolar I disorder. If approved, the drug is intended to provide the antipsychotic efficacy of olanzapine while mitigating olanzapine-associated weight gain.